Resources
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 17 February 2023
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 14th meeting on 17 February 2023.
healthdirect symptom checker
Use this tool if you’re feeling unwell and not sure what to do – if it’s an emergency, call 000 immediately. Answer some questions about your symptoms and get advice on whether to see a doctor, go to hospital or call an ambulance. It is available online at any time.
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK)
You can use the AUSDRISK tool to estimate your risk of getting type 2 diabetes in the next 5 years.
6:30
Top 3 questions – Healthy lifestyle choices
Professor Michael Kidd, Deputy Chief Medical Officer, discusses making healthy choices, and the small steps we can take every day to enjoy a healthy life.
5:44
Top 3 questions – Chronic Conditions
Hear Doctor Lucas De Toca, COVID-19 Primary Care Response First Assistant Secretary, talk about chronic illness.
00:06:33
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 1)
Hear from Dr Lucas de Toca talk about whether men are more susceptible to certain illnesses or conditions compared to women, and when men should start regular health checks and screening tests.
00:07:12
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 2)
In celebration of Men’s Health Week, hear from Dr Lucas de Toca on how family history and lifestyle impact our health and learn tips to help maintain a healthy lifestyle.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 14 October 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 13th meeting on 14 October 2022
Life Saving Drugs Program – Avalglucosidase alfa (Nexviazyme®) outcome statement
Summary of the consideration of the application from Sanofi Pty Ltd for the inclusion of avalglucosidase alfa (Nexviazyme®) on the Life Saving Drugs Program (LSDP) for the treatment of Pompe Disease.
Elosulfase alfa Terms of Reference and Protocol Questions
This report outlines the Elosulfase alfa 24 Month Review Terms of Reference and Protocol Questions
Providing health care to a thalidomide survivor fact sheet
This fact sheet is designed to help facilitate discussions between thalidomide survivors and their health care practitioners.
Coronavirus (COVID-19) at a glance – 20 June 2022
This infographic provides a quick view of the coronavirus (COVID-19) situation in Australia on 20 June 2022
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 24 June 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 12th meeting on 24 June 2022
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Evaluation of the Chronic Pain MedsCheck Trial – Final report
This report presents the results of the project to trial a pharmacist-led support service for patients who take medication to manage chronic pain.
National Site of Recognition Steering Committee communique – 20 January 2022
This communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
National Site of Recognition Steering Committee communique – 9 December 2021
Details of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.
National Site of Recognition Steering Committee communique – 1 November 2021
Details of the meeting of the National Site of Recognition for thalidomide survivors and their families Steering Committee held on 1 November 2021.
Australian National Diabetes Strategy 2021–2030
The Australian Government has developed a new national diabetes strategy. This strategy updates and prioritises the response to diabetes for all governments.
COVID-19 vaccination – vaccination data – 31 October 2021
This data file contains statistical data about Australia's COVID-19 vaccinations.
National Strategic Action Plan for Heart Disease and Stroke
The National Strategic Action Plan for Heart Disease and Stroke provides a roadmap to achieve a healthier Australia by tackling heart disease and stroke, two of the nation’s biggest killers.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 8th October 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 10th meeting on 8th October 2021.
Cerliponase alfa terms of reference and protocol questions
This report outlines the Cerliponase alfa 24 month review terms of reference and protocol questions
Date last updated: